<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58876">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02123134</url>
  </required_header>
  <id_info>
    <org_study_id>ATX-101-13-28</org_study_id>
    <nct_id>NCT02123134</nct_id>
  </id_info>
  <brief_title>Safety Study of ATX-101 for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age</brief_title>
  <official_title>A Multicenter, Double-blind, Placebo-controlled Safety Study of ATX-101 (Deoxycholic Acid Injection) for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kythera Biopharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kythera Biopharmaceuticals</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to explore the safety and efficacy of subcutaneous
      injections of ATX-101  relative to placebo, in the submental area of subjects who are 65 to
      75 years old.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">August 2015</completion_date>
  <primary_completion_date type="Anticipated">July 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and tolerability as assessed by adverse events</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessments using a clinician rating scale</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessments using patient reported scales</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy assessments using a laxity scale</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>PK plasma parameters following ATX-101 or placebo administration in a subset of subjects</measure>
    <time_frame>pre-dose, 15, 30, 45, 60, and 90 minutes, and 2, 4, 8, 12 and 24 hrs</time_frame>
    <safety_issue>No</safety_issue>
    <description>PK parameters will include area under the concentration time curve (AUC) from time zero to 24 hours, time to maximum concentration (tmax), maximum observed plasma concentration (Cmax) for both ATX-101 and placebo treated subjects.</description>
  </other_outcome>
  <other_outcome>
    <measure>Determination of deoxycholate plasma concentration in subset of subjects</measure>
    <time_frame>pre dose, week 16 OR week 24</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Safety and tolerability as assessed by treatment area evaluations</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Safety and tolerability as assessed by concomitant medications</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Safety and tolerability as assessed by clinical laboratory evaluations</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Safety and tolerability as assessed by vital sign measurements</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Safety and tolerability as assessed by physical examinations</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy assessments on submental fat using calipers</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <other_outcome>
    <measure>Efficacy assessments using standardized photography</measure>
    <time_frame>up to 32 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Submental Fat</condition>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ATX-101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ATX-101</intervention_name>
    <arm_group_label>ATX-101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 65 to 75 years of age

          -  Stable Body Weight

          -  Dissatisfaction with the submental area expressed by subject

          -  Acceptable volume of submental fat graded by clinician

          -  BMI of ≤40.0 kg/m2

          -  Signed informed consent (ICF)

        Exclusion Criteria:

          -  No prior intervention for SMF (eg liposuction, surgery or lipolytic agents)

          -  Absence of clinically significant health problems

          -  History of any intervention to treat SMF (eg liposuction, surgery, or lipolytic
             agents)

          -  Anatomical features for which reduction in SMF may result in aesthetically
             unacceptable outcome, judged by clinician

          -  History of trauma associated with the chin or neck areas  that in the judgment of the
             investigator may affect evaluation of safety or efficacy

          -  Body mass index of ≤ 40.0 kg/m2
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick Beddingfield, III, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Davis</last_name>
    <phone>1-877-284-1213</phone>
    <email>adavis@clinicalsiteservices.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Gary Monheit, M.D.</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pearl Grimes</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Susan Weinkle</name>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <zip>34209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>William Coleman, M.D.</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhoda Narins, M.D.</name>
      <address>
        <city>White Plains</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Robert Fixler, M.D.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45255</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 28, 2014</lastchanged_date>
  <firstreceived_date>April 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
